Biomed outlines obesity drug push with Phase 3 plan and nutraceutical launch

By AI, Created 11:13 AM UTC, May 20, 2026, /AGP/ – Biomed Industries says its oral obesity candidate NA-931 delivered up to 13.8% mean weight loss in a 13-week Phase 2 study and is moving toward Phase 3. The company is pairing that program with a Bioxentra nutraceutical platform meant to generate near-term revenue as the obesity market faces pricing pressure and patent changes.

Why it matters: - Biomed Industries is trying to build two revenue streams at once: a near-term nutraceutical business and a longer-term obesity drug franchise. - The strategy targets a crowded obesity market where oral GLP-1 pricing pressure and the expected loss of semaglutide patent protection in 2026 could reshape competition and margins. - The plan gives Biomed a way to seek early cash flow while advancing a differentiated therapy that aims to preserve muscle mass.

What happened: - Biomed Industries said CEO Dr. Lloyd L. Tran presented new clinical data on NA-931 at the Metabolic Medicine Summit in Boston on April 29-30, 2026. - The company also disclosed a strategic licensing agreement with Bioxentra Life Sciences. - NA-931 is described as a novel oral quadruple receptor agonist. - Biomed said the program is advancing toward Phase 3.

The details: - NA-931 produced up to 13.8% mean weight loss in a 13-week Phase 2 study with 125 patients. - The placebo group saw about 2% mean weight loss. - Seventy-two percent of patients reached at least 11% weight loss. - The therapy was generally well tolerated. - Most gastrointestinal adverse events were reported as insignificant or mild. - Biomed said 83% of GI events were classified as insignificant. - Mild nausea and vomiting occurred in 7.3% of treated subjects. - Diarrhea occurred in 6.3% of treated subjects. - No muscle loss was observed. - The company said there were no clinically meaningful differences in GI-related adverse events versus placebo. - NA-931 targets insulin-like growth factor-1, GLP-1, GIP and glucagon receptors. - The multi-target design is intended to support metabolic regulation and muscle preservation. - Bioxentra is being positioned as a metabolic companion platform. - The platform is designed to be used alongside GLP-1 therapies, before treatment starts, or after discontinuation. - Biomed said the companion platform could support muscle preservation during weight loss, improve metabolic readiness, and help with weight maintenance after treatment stops.

Between the lines: - Biomed is leaning into a common gap in current obesity care: patients may lose weight on GLP-1 drugs but still face tolerability issues, muscle loss concerns and rebound weight gain after stopping treatment. - The company is also trying to reduce dependence on a single drug timeline by pairing clinical development with a nutraceutical launch. - Dr. Tran said the business model is meant to generate near-term revenue while advancing a potentially best-in-class therapy. - Real-world data cited by the company suggest about half or more of patients stop GLP-1 therapy within a year, with some studies showing higher long-term discontinuation rates. - Those discontinuations are linked to adverse events, cost and access limits.

What’s next: - Biomed plans to move NA-931 into Phase 3 development. - Bioxentra is expected to launch as a nutraceutical platform for early commercialization. - The company is betting that multiple value inflection points — including the nutraceutical rollout, Phase 3 progress and potential regulatory milestones — will support investor interest. - Biomed says the strategy is designed to capture both short-term revenue growth and longer-term pharmaceutical value.

The bottom line: - Biomed is pairing a late-stage obesity drug with a companion nutraceutical business to try to win on speed, differentiation and cash flow in a fast-changing market.